Clarinex OTC Option “Valuable” In Face Of Competition – Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
The option to file an OTC switch application for Rx Clarinex (desloratadine) is an important part of Schering-Plough's strategy for growth, CEO Fred Hassan said during the firm's fiscal 2006 fourth-quarter earnings call Jan. 29